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a b s t r a c t
Here we provide data describing the time-course of blood-glucose and
ﬂuid-intake proﬁles of diabetic hemizygous human-amylin (hA) trans-
genic mice orally treated with rutin, and matched control mice treated
with water. We employed “parametric change-point regression analysis”
for investigation of differences in time-course proﬁles between the
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control and rutin-treatment groups to extract, for each animal, baseline
levels of blood glucose and ﬂuid-intake, the change-point time at which
blood glucose (diabetes-onset) and ﬂuid-intake (polydipsia-onset)
accelerated away from baseline, and the rate of this acceleration. The
parametric change-point regression approach applied here allowed a
muchmore accurate determination of the exact time of onset of diabetes
than do the standard diagnostic criteria. These data are related to the
article entitled “Rutin suppresses human-amylin/hIAPP misfolding and
oligomer formation in-vitro, and ameliorates diabetes and its impacts in
human-amylin/hIAPP transgenic mice” (J.F. Aitken, K.M. Loomes, I. Riba-
Garcia, R.D. Unwin, G. Prijic, A.S. Phillips, A.R.J. Phillips, D. Wu, S.D. Pop-
pitt, K. Ding, P.E. Barran, A.W. Dowsey, G.J.S. Cooper. 2016) [1].
& 2016 The Authors. Published by Elsevier Inc. This is an open access
article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
Speciﬁcations Table
Subject area Biology
More speciﬁc
subject area
Type 2 Diabetes, parametric regression analysis
Type of data Figure, Table
How data were
acquired
Blood glucose measurements (Advantage II, Roche Diagnostics), ﬂuid intake
measurement in rutin-treated and control human amylin transgenic mice
Data format Analyzed
Experimental
factors
Treatment of human amylin transgenic mice with either rutin (0.5 mg/ml in the
drinking water) or water from 21 days of age (weaning)
Experimental
features
Weekly blood glucose and ﬂuid intake measurements
Data source
location
University of Auckland, Auckland, New Zealand
Data accessibility Data are presented in this article
Value of the data
 These data will be of value to the scientiﬁc community working in the area of type-2 diabetes and
anti-diabetic therapies since they illustrate the inhibitory effect of a small orally-active molecule on
two speciﬁc biological parameters reﬂecting the progression of diabetes in a model that closely
mirrors the human disease.
 These data will also be of value to biostatisticians working in the area of pre-clinical treatment
investigations, as they present a new Bayesian statistical approach for analysing the effect of drug
treatment on a key diagnostic criterion employed for diagnosis of diabetes in patients and diabetic
animals.
 This new Bayesian approach could ﬁnd application in the evaluation of future therapies for diabetes or
other diseases, which have biological parameters that are analysed for clinically relevant impacts.
1. Data
Here we present data illustrating the effects of the dietary ﬂavonol rutin on the blood-glucose (see
Fig. 1A) and ﬂuid-intake proﬁles (Fig. 1B) of h-amylin transgenic male mice and their non-transgenic
littermates versus mice treated with water (vehicle) only.
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We employ a novel parametric change-point regression analysis to extract, for each animal,
baseline levels of blood glucose and ﬂuid intake, the change-point time at which blood glucose
(diabetes-onset) and ﬂuid intake (onset of polydipsia) accelerated away from baseline, and the rate of
this acceleration (Table 1). This enabled more exact measurement of the impact of rutin on the
survival of diabetic mice.
2. Experimental design and methods
2.1. Human-amylin transgenic mice
Protocols were approved by the University of Auckland Animal Ethics Committee and performed
in accordance with the New Zealand Animal Welfare Act (1999), the U.K. Animals (Scientiﬁc Proce-
dures) Act 1986, and associated guidelines. All protocols complied with the ARRIVE guidelines [2]. The
Fig. 1. A. Blood-glucose proﬁles of non-transgenic animals (points) and transgenic littermates (crosses) for the investigation of
rutin treatment in hA-transgenic mice (n¼12 control pairs, n¼10 rutin-treated pairs). For each pair, the pair's weaning and the
transgenic's day of death are shown as black-vertical lines. Each time-course is centred on the transgenic's most likely day of
diabetes-onset (red-vertical line), which was inferred by parametric change-point regression analysis as the time point at which
the proﬁle changes from a constant baseline to a constant acceleration from baseline. The most likely ﬁtted proﬁle (joint
posterior mode) is shown for each transgenic (red curve) and non-transgenic (dashed-red line). The uncertainty of the ﬁt is
illustrated for each transgenic's proﬁle (grey, 95% credible interval) and diabetes-onset change-point (red posterior distribution
positioned over the x-axis at day zero). Results for the conventional method for determining diabetes onset (two consecutive
weekly measurements 411 mM) are also shown (dotted-red vertical lines), illustrating the inaccuracy and therefore limited
utility of this approach for sensitive between-treatment comparisons. Fig. 1B. Fluid-intake proﬁles of non-transgenic animals
(points) and transgenic littermates (crosses) corresponding to the blood-glucose proﬁles shown in Fig. 1A. Data points removed
before parametric modelling are greyed out. Each time-course is centred on the transgenic's most likely ﬂuid-intake change-
point (blue-vertical line), with the respective blood-glucose change-point from Fig. 1A superimposed (red-vertical line). The
most likely ﬁtted proﬁle (joint-posterior mode) is shown for each transgenic (blue curve) and non-transgenic littermate
(dashed-blue line). The uncertainty of the ﬁt is shown for each transgenic's proﬁle (grey, 95% credible interval), and the change-
points for blood glucose and ﬂuid-intake (red and blue posterior distributions respectively, both positioned over the x-axis at their
respective change-points). These posterior distributions illustrate that the ﬂuid-intake change-points are estimated with more
certainty than the blood-glucose change-points.(For interpretation of the references to colour in this ﬁgure legend, the reader is
referred to the web version of this article)
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Table 1
Metadata and parameters inferred from parametric change-point modelling of the control and rutin-treated transgenic mice, together with corresponding results for non-parametric
survival analysis (two-tailed Wilcoxon test) and parametric testing (two-tailed t-test).
Treatment ID Study metadata Parameters inferred from blood glucose model Parameters inferred from ﬂuid intake model Inferred
from both
models
Transgenic Transgenic Normal Transgenic Normal Transgenic
Wean to
Death
(Days)
Wean to
Diagnosis
(Days)
Diagnosis
to Death
(Days)
Wean to
Change-
point
(Days)
Change-
point to
Death
(Days)
Acceleration
from Base-
line (log
mM2/Day)
Baseline
(mM)
Baseline
(mM)
Wean to
Change-
point
(Days)
Change-
point to
Death
(Days)
Acceleration
from Base-
line (log
mM2/Day)
Baseline
(ml)
Baseline
(ml)
Change-
point to
change-
point
(Days)
Control 1 514 257 257 342 172 5.4 10.2 7.9 383 131 3.7 4.0 3.6 40
2 363 217 146 193 170 5.7 9.8 7.6 246 117 3.8 3.9 3.1 53
3 168 44 124 61 107 4.7 9.9 7.1 91 77 3.5 4.5 3.7 30
4 194 97 97 88 106 4.1 10.8 7.8 104 90 3.6 4.6 4.3 17
5 331 253 78 233 98 4.6 9.0 7.6 274 57 0.7 3.8 – 41
6 158 68 90 63 95 3.8 10.9 7.9 90 68 1.0 5.4 4.0 27
7 182 118 64 97 85 4.1 8.9 7.5 114 68 3.0 7.4 4.4 17
8 276 217 59 198 78 5.2 9.0 8.0 238 38 3.8 4.2 3.7 40
9 95 41 54 19 76 4.5 9.1 8.0 50 45 3.2 4.7 5.0 31
10 155 83 72 85 70 3.4 10.1 7.4 98 57 2.7 4.2 4.4 13
11 143 93 50 76 67 2.0 9.5 7.9 80 63 2.6 4.6 3.9 4
12 236 195 41 177 59 3.2 8.5 7.9 186 50 2.6 8.0 3.6 10
Rutin 1 441 241 200 215 226 6.3 9.5 6.5 295 146 4.7 4.5 4.5 80
2 295 58 237 75 220 6.6 10.9 8.2 174 121 3.4 4.9 4.3 99
3 251 37 214 56 195 6.2 10.5 7.4 129 122 5.0 4.5 4.1 73
4 213 78 135 33 180 6.2 9.5 7.7 121 92 3.0 5.9 5.3 87
5 353 201 152 184 169 5.8 9.3 7.7 243 110 3.4 4.6 4.9 58
6 277 153 124 117 160 5.1 8.9 7.3 154 123 4.1 4.5 4.6 36
7 302 70 232 142 160 5.6 11.5 7.4 193 109 4.2 4.5 5.0 51
8 161 71 90 49 112 4.8 8.7 7.5 79 82 3.7 4.8 4.5 29
9 129 60 69 41 88 3.2 8.1 7.5 55 74 2.4 4.4 3.8 13
10 140 78 62 62 78 3.6 9.1 8.1 79 61 2.8 5.4 4.6 17
test Wilcoxon Wilcoxon Wilcoxon Wilcoxon Wilcoxon t-test t-test t-test Wilcoxon Wilcoxon t-test t-test t-test Wilcoxon
0.582 0.222 0.044 0.228 0.011 0.030 0.932 0.276 0.974 0.014 0.059 0.744 0.009 0.036
estimate 29 24 63 27 68 1.1 0.0 0.2 1.4 35 0.8 0.1 0.6 27.0
95% CI lower 63 137 0 123 9 2.1 0.9 0.6 92.1 6 1.6 1.0 0.2 0.3
95% CI upper 122 26 135 33 109 0.1 0.8 0.2 73.5 60 0.0 0.8 1.0 54.3
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experimental design for rutin versus water treatment of hA transgenic mice and collection of blood
glucose and ﬂuid intake data are described in [1].
2.2. Modelling of time-dependent glucose and ﬂuid-intake data in rutin- and control-treatment groups
For modelling of time-dependent glucose and ﬂuid intake data in rutin- and control-treatment
groups (Fig. 1A,B), we constructed a non-linear parametric change-point regression model, where
each of the three inferred parameters had a clear biological interpretation: (i) A constant baseline
component; (ii) A change-point in time where blood glucose or ﬂuid intake begins to deviate from
this baseline; (iii) A log-transformed constant acceleration from baseline, beginning at the inferred
change-point. The maximum likelihood solution to parametric change-point regression in general is a
highly non-convex optimisation problem [3], necessitating grid search or similar. To this end, we
performed a Bayesian simulation to sample the posterior distribution of the three parameters for each
animal, plus a single normally-distributed residual variance parameter across all animals. All para-
meters were assigned uninformative uniform prior distributions (truncated to between weaning and
death for the change-point parameters, and restricted to non-negative values for the variance para-
meter). The Stan Hamiltonian Monte Carlo software [4] was employed, which efﬁciently sampled the
posterior distribution despite strong correlation between the change-point and acceleration para-
meters of each animal. Four chains of 218 iterations (of which 217 were warm-up iterations and with
thinning factor 25) were generated from over-dispersed starting values. On the result, the Gelman–
Rubin convergence diagnostic [5] strongly suggested the posterior was sampled evenly and not
affected by local minima (Rhato1.01 and effective sample size 4400 for all parameters). From the
generated samples, Fig. 1A, B show the 95% intervals of Highest Posterior Density (HPD) for the
predicted time-courses, and the full posterior distributions for the change-point parameters. These
indicate predominantly unimodal ﬁt, together with reasonable estimation uncertainty. Finally, from
the marginal posterior of each parameter, the median was extracted and used to seed a maximum
likelihood ﬁt to the joint posterior mode, as illustrated. The parameter values for this joint posterior
mode are presented in Table 1, and were subsequently used for downstream statistical testing.
Glucose measurements were right-censored (at 430.0 mM), which was modelled appropriately
by the parametric change-point regression analysis model likelihood.
Modelling of the ﬂuid-intake time-course is shown in Fig. 1B. The ﬂuid-intake time-course had a
more complex structure. Firstly, there is typically a transient increase in ﬂuid-intake during adoles-
cence and secondly, ﬂuid-intake in late-stage polydipsia was highly variable between animals. Since
the ﬁrst phenomenon is not directly of interest, we mitigated most of its inﬂuence by removing from
the analysis all data-points corresponding to times less than the lower HPD boundary of the
respective animal's inferred blood-glucose change-point. As no inference can be made from the
second phenomenon within the current sample size, we removed its effect by right censoring
measurements above 30.0 ml/day.
The modelling and inference then proceeded identically (Fig. 1B) to that for the blood-glucose
model (Fig. 1A). Inﬂexion points in longitudinal data were determined by parametric change-point
regression analysis, which enabled objective ﬁtting of time-response curves (Fig. 1A, B; Table 1).
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